Longeveron

(NASDAQ) LGVN

Current Price$0.62

Market Cap$19.65M

Since IPO (2021)-99%

5 Year-99%

1 Year-60%

1 Month-26%

Longeveron last closing stock price
Metric	Price	Date
Last close	USD 0.62	2026-07-17

Longeveron stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-7.85%	USD 0.68	2026-07-10
1 month	-25.95%	USD 0.84	2026-06-17
3 month	-43.45%	USD 1.10	2026-04-17
Year to date	+22.92%	USD 0.51	2025-12-31
1 year	-59.61%	USD 1.54	2025-07-17
3 year	-98.2%	USD 34.50	2023-07-18
5 year	-99.01%	USD 62.80	2021-07-16
Since inception	-99.16%	USD 74.10	2021-02-12

Longeveron Financials at a Glance

Market Cap

$19.65M

Revenue (TTM)

$1.22M

Net Income (TTM)

-$22.43M

EPS (TTM)

-$1.16

P/E Ratio

-0.54

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$0.62

Volume

202,176

Open

$0.61

Price

$0.62

Volume

202,176

Open

$0.61

Previous Close

$0.62

Daily Range

$0.59 - $0.63

52-Week Range

$0.48 - $1.80

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$0.62

Volume

202,176

Open

$0.61

Previous Close

$0.62

Daily Range

$0.59 - $0.63

52-Week Range

$0.48 - $1.80

Estimated Earnings Date

Aug 12, 2026

LGVN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Longeveron

Longeveron develops cell-based therapies for people with aging-related and rare diseases. Its main product aims to help those with heart defects or memory loss. The company’s treatments are still in clinical trials and not yet approved for sale.

Cell Science, Simplified: What Longeveron Sells

Laromestrocel (Lomecel-B): Cell therapy for heart defects, Alzheimer’s, and frailty; 83% of 2025 revenue from clinical trial fees.
Contract Manufacturing: Produces cell therapies for other companies; 17% of 2025 revenue, but declining.
Bahamas Registry Trial: Offers therapy to eligible patients in private clinics; main source of clinical trial revenue.

Growth Spurts and Growing Pains

Listed on NASDAQ in 2021, expanding public access to capital.
Partnered with University of Miami and U.S. government agencies for clinical research since 2014.
Launched pivotal Phase 2b trial for heart defect therapy in 2025.
Discontinued Japan frailty trial in 2024 due to regulatory hurdles.
Raised $15.9 million in private placement in March 2026 to support operations.

What Makes Longeveron Stand Out

Longeveron focuses on cell therapies for conditions with few treatment options. It operates its own manufacturing facility and holds patents for its technology. The company collaborates with universities and government agencies to advance clinical research.

Five Things You Need to Know

Revenue was $1.2 million in 2025, down 50% from 2024.
Net loss was $22.7 million in 2025, up 41% from 2024.
Cash and equivalents were $4.7 million at December 31, 2025.
Operating expenses rose 31% to $24.1 million in 2025.
Raised $15.9 million in March 2026 to address liquidity concerns.

Bottom Line

Longeveron is a small biotech focused on cell therapies for hard-to-treat diseases. The company faces financial challenges but continues to develop its clinical pipeline and partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Stephen H. Willard

Website

www.longeveron.com

Headquarters

Miami, FL 33136, US

LGVN Financials

Key Financial Metrics (TTM)

Gross Margin

65.13%

Operating Margin

-1881.66%

Net Income Margin

-1844.49%

Return on Equity

-202.41%

Return on Capital

-358.32%

Return on Assets

-105.75%

Earnings Yield

-1.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.65M

Shares Outstanding

31.60M

Volume

202.18K

Avg. Volume

341.03K

Financials (TTM)

Gross Profit

$792.00K

Operating Income

-$22.88M

EBITDA

-$21.37M

Operating Cash Flow

-$18.32M

Capital Expenditure

-$465.00K

Free Cash Flow

-$18.76M

Cash & ST Invst.

$15.76M

Total Debt

$748.00K

Longeveron Performance Analysis

Longeveron annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 1,222,000	-6.4%
2023	2023-12-31	USD 709,000	-42.0%
2024	2024-12-31	USD 2,392,000	237.4%
2025	2025-12-31	USD 1,199,000	-49.9%

Longeveron sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-17.1%
Q3	2025-09-30	-56.6%
Q4	2025-12-31	166.4%
Q1	2026-03-31	9.0%

Longeveron annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -8.98	10.0%
2023	2023-12-31	USD -10.22	13.8%
2024	2024-12-31	USD -2.62	-74.4%
2025	2025-12-31	USD -1.29	-50.6%

Longeveron sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	2.9%
Q3	2025-09-30	-18.2%
Q4	2025-12-31	38.5%
Q1	2026-03-31	20.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$398.00K

+4.5%

Gross Profit

$264.00K

-4.0%

Gross Margin

66.33%

N/A

Market Cap

$19.65M

N/A

Market Cap/Employee

$517.21K

N/A

Employees

N/A

Net Income

-$4.74M

+5.5%

EBITDA

-$4.48M

+2.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$15.76M

+10.0%

Total Debt

$748.00K

-42.2%

Accounts Receivable

$68.00K

+134.5%

Inventory

$0.00

N/A

Long Term Debt

$60.00K

-91.0%

Short Term Debt

$688.00K

+9.0%

Return on Assets

-1.06%

N/A

Return on Invested Capital

-1.36%

N/A

Free Cash Flow

-$4.37M

+9.8%

Operating Cash Flow

-$4.37M

+7.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

DAREDare Bioscience, Inc.

DAREDare Bioscience, Inc.$1.96+1.03%

ATHAAthira Pharma, Inc.

ATHAAthira Pharma, Inc.$6.75-6.12%

CRISCuris, Inc.

CRISCuris, Inc.$4.63-7.03%

LPTXLeap Therapeutics, Inc.

LPTXLeap Therapeutics, Inc.$0.77-3.15%

PULMPulmatrix, Inc.

PULMPulmatrix, Inc.$1.69+4.97%

CTXRCitius Pharmaceuticals, Inc.

CTXRCitius Pharmaceuticals, Inc.$0.50-2.88%

PCSAProcessa Pharmaceuticals, Inc.

PCSAProcessa Pharmaceuticals, Inc.$2.31+3.13%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$6.53-0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98-0.04%

NFLXNetflix

NFLXNetflix$68.95-0.07%

NOKNokia

NOKNokia$10.12-0.03%

PATHUiPath

PATHUiPath$12.15+0.01%

JOBYJoby Aviation

JOBYJoby Aviation$7.23-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$17.28-0.00%

Questions About LGVN

What is the current price of Longeveron?

Longeveron is trading at $0.62 per share.

What is the 52-week range for Longeveron?

Over the past 52 weeks, Longeveron has traded between $0.48 and $1.80.

How much debt does Longeveron have?

As of the most recent reporting period, Longeveron reported total debt of $748.00K.

How much cash does Longeveron have on hand?

Longeveron reported $15.76M in cash and cash equivalents in its most recent financial results.

What is Longeveron’s dividend yield?

Longeveron does not currently have a dividend yield.

Longeveron

Longeveron Financials at a Glance

LGVN News

Longeveron Posts 32% Revenue Drop in Q2

Here's Why Longeveron Stock Jumped Higher on Wednesday

Is It Too Late to Buy Longeveron Stock?

Why Longeveron Stock Skyrockted 661.2% in November

Is Longeveron a Good Biotech Stock to Buy?

Here's Why Longeveron Is Surging Today

Why Longeveron Stock Is Skyrocketing Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Longeveron

Cell Science, Simplified: What Longeveron Sells

Growth Spurts and Growing Pains

What Makes Longeveron Stand Out

Five Things You Need to Know

Bottom Line

LGVN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Longeveron Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About LGVN

What is the current price of Longeveron?

What is the 52-week range for Longeveron?

How much debt does Longeveron have?

How much cash does Longeveron have on hand?

What is Longeveron’s dividend yield?

Premium Investing Services